BidaskClub upgraded shares of Insulet (NASDAQ:PODD) from a buy rating to a strong-buy rating in a research report released on Saturday morning, BidAskClub reports.

Other analysts have also recently issued reports about the stock. ValuEngine cut shares of Virtu Financial from a hold rating to a sell rating in a research report on Tuesday, June 18th. JPMorgan Chase & Co. cut shares of Sogou from a neutral rating to an underweight rating and decreased their price target for the stock from $5.50 to $4.12 in a research report on Thursday, June 27th. Canaccord Genuity decreased their price target on shares of Jamieson Wellness from C$23.00 to C$20.00 in a research report on Monday, May 6th. UBS Group set a €110.00 ($127.91) price target on shares of Wacker Chemie and gave the stock a buy rating in a research report on Thursday, June 13th. Finally, Svb Leerink reaffirmed an outperform rating on shares of Stryker in a research report on Wednesday, July 10th. Five equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. The stock currently has an average rating of Buy and a consensus price target of $113.45.

Shares of NASDAQ PODD opened at $119.68 on Friday. Insulet has a 52-week low of $70.80 and a 52-week high of $124.38. The company’s fifty day moving average is $116.33. The stock has a market cap of $7.18 billion, a PE ratio of 2,393.60 and a beta of 1.12. The company has a debt-to-equity ratio of 2.68, a current ratio of 4.36 and a quick ratio of 3.71.

Insulet (NASDAQ:PODD) last announced its quarterly earnings results on Thursday, May 2nd. The medical instruments supplier reported $0.07 earnings per share for the quarter, topping analysts’ consensus estimates of $0.02 by $0.05. Insulet had a net margin of 2.37% and a return on equity of 7.01%. The firm had revenue of $159.56 million during the quarter, compared to analysts’ expectations of $154.66 million. During the same period in the prior year, the company earned ($0.11) EPS. The firm’s revenue was up 29.1% on a year-over-year basis. On average, sell-side analysts forecast that Insulet will post 0.27 earnings per share for the current fiscal year.

In other Insulet news, COO Charles Alpuche sold 3,900 shares of the business’s stock in a transaction on Wednesday, May 15th. The shares were sold at an average price of $104.78, for a total value of $408,642.00. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, insider Shacey Petrovic sold 895 shares of the business’s stock in a transaction on Wednesday, June 5th. The stock was sold at an average price of $113.00, for a total transaction of $101,135.00. Following the completion of the transaction, the insider now owns 95,559 shares in the company, valued at approximately $10,798,167. The disclosure for this sale can be found here. Insiders sold a total of 41,894 shares of company stock worth $4,524,025 in the last quarter. 3.50% of the stock is currently owned by company insiders.

A number of hedge funds have recently modified their holdings of PODD. Norges Bank acquired a new position in Insulet in the 4th quarter worth $53,604,000. William Blair Investment Management LLC lifted its holdings in Insulet by 15.7% in the 1st quarter. William Blair Investment Management LLC now owns 2,144,988 shares of the medical instruments supplier’s stock worth $203,967,000 after buying an additional 290,790 shares in the last quarter. Frontier Capital Management Co. LLC lifted its holdings in Insulet by 12.3% in the 1st quarter. Frontier Capital Management Co. LLC now owns 1,958,736 shares of the medical instruments supplier’s stock worth $186,256,000 after buying an additional 214,033 shares in the last quarter. Artisan Partners Limited Partnership raised its stake in shares of Insulet by 17.6% in the 1st quarter. Artisan Partners Limited Partnership now owns 1,391,041 shares of the medical instruments supplier’s stock valued at $132,274,000 after purchasing an additional 207,780 shares in the last quarter. Finally, KAMES CAPITAL plc raised its stake in shares of Insulet by 22.7% in the 1st quarter. KAMES CAPITAL plc now owns 582,252 shares of the medical instruments supplier’s stock valued at $55,372,000 after purchasing an additional 107,828 shares in the last quarter.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company offers Omnipod System, which consists of self-adhesive disposable tubeless Omnipod device (the pod) that delivers insulin into the body; and Personal Diabetes Manager, a handheld wireless device, which programs the Pod.

Further Reading: Hedge Funds – Risk or Reward?

Analyst Recommendations for Insulet (NASDAQ:PODD)

Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.